Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The increasing incidence of hepatocellular carcinoma (HCC) is becoming a considerable problem in Europe. While no national surveillance programme exists, there is increasing evidence that surveillance programmes are efficacious and may be cost-effective. The prognosis of large, symptomatic HCC is poor and only palliative treatment is available. In contrast small tumours are now amenable to several modes of treatment including liver transplantation, surgical resection and loco-regional ablation with acceptable 5 year survival rates. Therefore, the identification of small lesions through screening should prolong survival. Consequently, the European Association for the Study of the Liver (EASL) has recommended surveillance with ultrasound scans and tests for alpha fetoprotein every 6 months. Screening is now routine clinical practice in many parts of the developed world.

Original publication

DOI

10.1097/00042737-200505000-00004

Type

Journal article

Journal

Eur J Gastroenterol Hepatol

Publication Date

05/2005

Volume

17

Pages

491 - 496

Keywords

Biomarkers, Tumor, Carcinoma, Hepatocellular, Humans, Liver Neoplasms, Mass Screening, Population Surveillance, Prognosis, Survival Analysis